Year in Review: Updates in DLBCL Treatment | Supplements And Featured Publications

Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL

September 30, 2020

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

FDA Approvals Augment Advances Made in the DLBCL Armamentarium

August 11, 2020

John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.

x